Mail

0RA9.L - ABIVAX Société Anonyme

LSE - LSE Delayed price. Currency in EUR

ABIVAX Société Anonyme

7-11 boulevard Haussmann
Paris 75009
France
33 1 53 83 08 41
https://www.abivax.com

Sector(s):
Industry:
Full-time employees: 22

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Philippe Pouletty M.D., Ph.D.	Founder & Director	N/A	N/A	1958
Mr. Marc M. P. de Garidel M.B.A.	CEO & Interim Chair of Board	N/A	N/A	1958
Mr. Didier Blondel	EVP, CFO & Board Sec.	N/A	N/A	N/A
Ms. Raquel Lizarraga	Investor Relations Mang.	N/A	N/A	N/A
Ms. Regina Jehle	VP of Communications	N/A	N/A	N/A
Anne Pascard	HR Mang.	N/A	N/A	N/A
Mr. Pierre Courteille M.B.A.	Chief Bus. Officer	N/A	N/A	N/A
Mr. Sheldon Sloan	Chief Medical Officer	N/A	N/A	N/A
Mr. Michael Ferguson B.S., M.B.A.	Chief Commercial Officer	N/A	N/A	N/A
Mr. Paul Gineste	VP Clinical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that modulate the body's natural immune system to treat patients with chronic inflammatory, infectious, and cancer diseases. The company's products include obefazimod that is in Phase III clinical trials for the treatment of ulcerative colitis; Phase IIb clinical trials for the treatment of Crohn's Disease; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and in a pre-clinical trial for the treatment of Respiratory Syncytial Virus. It also develops ABX 196, an immune enhancer candidate that is in Phase 2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue, influenza, and respiratory syncytial virus. It has license agreement with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Corporate governance

ABIVAX Société Anonyme’s ISS governance QualityScore as of 1 May 2023 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.